RecruitingNCT06089590

Ibd CAncer and seRious Infections in France (I-CARE 2)

Sponsor

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

Enrollment

6,000 participants

Start Date

Jan 25, 2024

Study Type

OBSERVATIONAL

Conditions

Crohn Disease Ulcerative Colitis IBD

Summary

This is a French prospective longitudinal observational multicentre cohort study. Primary objective : to assess prospectively the presence and the extent of safety concerns (cancer, serious infections, arterial and venous thrombotic events) in patients with CD and UC and treated with JAKi, anti-IL23p19, and S1p modulators.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is following people with inflammatory bowel disease (IBD) — including Crohn's disease and ulcerative colitis — in France to track serious events like cancer and infections over time. The goal is to understand the long-term risks associated with IBD and its treatments through a large real-world registry. **You may be eligible if...** - You have a confirmed diagnosis of Crohn's disease, ulcerative colitis, or unclassified IBD - You are 18 or older - You are willing to share your contact information and complete electronic surveys - You agree to be contacted by the study team and your gastroenterologist during the study **You may NOT be eligible if...** - You are unable to sign the consent form - You do not have regular internet access - You are enrolled in a randomized clinical trial where your treatment is blinded (unknown) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.